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RNA-based vaccine represents an irresistible and safe immunization strategy with
decreasing theoretical risks of genomic integration and malignant cell transformation. To
our knowledge, however, there is no report about development of RNA vaccine against
Toxoplasma gondii infection. We have previously demonstrated that the recombinant
T. gondii nucleoside triphosphate hydrolase-II (NTPase-II) protein is able to provide
protective Th1 cell-mediated immunity against T. gondii. Herein, we evaluated the
immunogenic potential of a self-amplifying RNA vaccine-encoding T. gondii NTPase-
II gene, RREP-NTPase-II, delivered by a synthetic lipid nanoparticle (LNP). Immunization
of mice with naked RREP-NTPase-II induced a strong cellular and humoral immune
response with high-IgG antibody titers and IFN-γ production. The immunized mice
displayed significantly prolonged survival time and reduction in brain parasite load
(46.4%) compared with control group. Furthermore, mice vaccinated with RREP-
NTPase-II-encapsulated LNP displayed significantly enhanced protection against acute
infection as well as chronic infection with PRU cyst, which shows 62.1% reduction
in brain cyst burden in comparison to control group. These results suggest that the
combination of self-amplifying RNA and LNP ion would be beneficial to the development
of a safe and long-acting vaccine against toxoplasmosis.
Keywords: Toxoplasma gondii, vaccine, nucleoside triphosphate hydrolase, self-amplifying RNA, lipid
nanoparticle (LNP)
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INTRODUCTION
Toxoplasma gondii, the pathogen of toxoplasmosis, is an obligate
intracellular parasitic protozoan, which has a wide range of
hosts including humans and warm-blooded animals (Cenci-Goga
et al., 2011). Hosts could be infected through consumption of
raw or undercooked meat of animals containing Toxoplasma
cysts, or through ingestion of water or vegetables contaminated
with Toxoplasma oocysts. Although T. gondii infection is usually
asymptomatic in immunocompetent hosts, it is a serious threat to
pregnant and immunocompromised individuals (Dubey, 2010).
Vaccines against Toxoplasma have been explored for a long
time. However, ToxoVax, based on live attenuated S48 strain,
is only one commercial vaccine for farm animals (Buxton
and Innes, 1995). But it is unlikely to be applied to humans
because of limitations of reduced efficacy as well as biosafety
concerns (Zhang et al., 2013). To surmount this defect, current
development trials of vaccines against T. gondii infection have
been focused mainly on the subunit, recombinant, and nucleic
acid vaccines (Jongert et al., 2009; Zhang et al., 2013). Among
these different approaches, development of nucleic acid-based
vaccine is a promising approach due to less expense, easiness to
handle, as well as its ability to induce both humoral and cellular
immune responses with low dose (Tang et al., 1992). To our
knowledge, however, there is no report about development of
RNA vaccine against T. gondii infection although plasmid-based
DNA vaccines have been paid attention for several decades (Liu
et al., 2012). The main obstacles to the development of RNA
vaccine could be attributed to that RNA vaccine often elicits weak
immune responses and requires multiple vaccinations because
of the short intracellular half-life and easiness of degradation
in vivo and during storage. Nonetheless, RNA-based vaccination
still exhibits an irresistible advantage that RNA molecule exists
solely in the cytoplasm, thereby extensively decreasing theoretical
risks of genomic integration and malignant cell transformation,
which give rise to safety concerns for DNA vaccines (Kofler et al.,
2004). That is why RNA vaccination is not categorized as gene
therapy by regulatory authorities. Thus far, the non-amplifying
mRNA vaccines have been utilized in experimental animals for
elicitation of humoral and cellular immune responses against
tumor (Pascolo, 2008; Fotin-Mleczek et al., 2011), allergy (Weiss
et al., 2012), and infectious disease (Lorenzi et al., 2010).
Recently, a self-amplifying RNA vector, pRREP, based on an
alphavirus Semliki Forest virus (SFV) genome has been utilized
to improve the weak immune responses induced by mRNA
vaccines (Fleeton et al., 2001; Johansson et al., 2012). The skeleton
of self-amplifying RNA mainly consists of the gene encoding
the viral RNA replicase and the antigen of interest (AOI)-
encoding mRNA, which replaces the viral structural protein
gene. Upon transfection, the AOI would be plentifully expressed
by the replicase complex amplification in the cytoplasm of the
transfected cells (Karlsson and Liljestrom, 2004). In addition,
this strategy avoids safety concerns and complicated operation
because the RNA could be directly prepared by transcribing a
linearized DNA plasmid using a T7 RNA polymerase in vitro
(Johansson et al., 2012). Moreover, a synthetic lipid nanoparticle
(LNP) delivery system has been utilized to deliver self-amplifying
RNA in order to further enhance the vaccination efficiency in vivo
(Geall et al., 2012; Hekele et al., 2013).
Toxoplasma gondii nucleoside triphosphate hydrolase
(NTPase), accounting for 2–8% of the total protein of tachyzoites,
has a potent apyrase activity and is released from dense granules
into parasitophorous vacuole for successively degrading ATP to
ADP and finally AMP (Asai et al., 1983; Nakaar et al., 1998). Two
isoforms of NTPase have been verified in T. gondii. However,
NTPase-I is expressed only in type I virulent strains, while
NTPase-II generally exists in all strains (Asai et al., 1995). This
difference indicates the possibility that NTPase-II might be more
preferable as a potential vaccine candidate than NTPase-I, and
this speculation is supported by the finding that the recombinant
NTPase-II protein could elicit a strong specific Th1 immune
response and partially protect the experimental mice from acute
and chronic Toxoplasma infection (Tan et al., 2011).
In this study, we evaluated the potency of a self-amplifying
RNA, RREP-NTPase-II, to induce specific immune response
and protective efficiency anti-Toxoplasma challenge in BALB/c
mice and tested further whether LNP delivery system effectively
improves the immune response. We found that RREP-NTPase-
II indeed elicited both humoral and cellular immune responses
that could be enhanced by LNP encapsulation, indicating that the
combination of self-amplifying RNA vaccine and LNP delivery
system is a promising approach with an improved safety and
immunogenicity profile.
MATERIALS AND METHODS
Mice
Female BALB/c mice and ICR mice (6–8 weeks old) were
purchased from Laboratory Animal Center, Wenzhou Medical
University, Zhejiang, China. They were bred and handled in strict
accordance with the Good Animal Practice requirements of the
Animal ethics Procedures and Guidelines of China. This research
was approved by the Laboratory Animal Ethics Committee of
Wenzhou Medical University (Permit number: wydw2015-0073).
Humane endpoints are considered to avoid the mice pain or
suffering via euthanasia. Mice were monitored daily for signs of
toxoplasmosis, such as fatigue, difficulty in feeding and severe
ascites. Mice shown above signs would be sacrificed immediately
with CO2 gas.
Parasites
The cyst-forming type II strain PRU was maintained in female
ICR mice. Forty-five days after infection, cysts were harvested
from infected mouse brains for challenge of immunized mice.
The virulent type I strain RH was routinely propagated in human
foreskin fibroblast (HFF) as previously described (Li et al., 2016)
and employed for acute challenge infection.
Plasmid Construction and RNA
Synthesis
The DNA sequence of NTPase-II gene was amplified from
the construct pBAD-HisB-NTPase-II (Tan et al., 2011)
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using a set of specific primers 5′-TTCCCGGGATGACAG
ACTCATCGTCACTCC-3′ and 5′-CCACTAGTTCACAGATT
GTGAGAATATCCCGCC-3′ and was inserted into Xma I and
Spe I site of pRREP-eGFP (Karlsson and Liljestrom, 2004) to
swap the coding sequence of eGFP. The resulting plasmid,
pRREP-NTPase-II, was purified with E.Z.N.A. R© Plasmid Mini
Kit (OMEGA Bio-tek, USA) and stored at −20◦C. Prior
to immunization, the plasmids were linearized and RNAs
in vitro transcription were made by using MEGAScriptTM Kit
(Ambion, USA) as described previously (Geall et al., 2012).
Finally, the purified transcribed RNAs were capped with
Vaccinia Capping System (NEB, USA) before encapsulation
(Figure 1A).
Detection of Expression of NTPase-II
In vitro
The self-amplifying RNA was transfected into 293T cells at once
post-transcription according to the manufacturer’s instructions
of Lipofectamine R© 2000 Reagent (Invitrogen, USA). Twenty-four
hours after transfection, expression of NTPase-II was confirmed
by indirect immunofluorescence assay (IFA) with the mouse
FIGURE 1 | Characterization of self-amplifying RNA. (A) Flow diagram of development of a self-amplifying RNA vaccine, RREP-NTPase-II, based on an
alphavirus Semliki Forest virus (SFV) RNA vector. polyA, polyadenylation signal; 26S, the subgenomic promoter of SFV; eGFP, enhanced green fluorescent protein
gene; NTPase-II, the full CDS of Toxoplasma gondii NTPase-II gene without the signal peptide; nSP1–4, the non-structural protein genes of SFV.
(B) Immunofluorescence assay (IFA). The self-amplifying RNA was transiently transfected into 293T cells and the expression of NTPase-II was identified by IFA using
specific-NTPase-II monoclonal antibody. Scale bars, 100 µm. (C) Western blot analysis. Cell lysates were separated by SDS–PAGE and NTPase-II was visualized
using anti-NTPase-II monoclonal antibody. Recombinant NTPase-II (rNTPase-II) was loaded as positive control, cell lysates from either non-transfected cells (293T)
or transfected with RREP-eGFP (RREP-eGFP) as negative control. (D) RNase protection evaluation. Before and after exposure to RNase A, RNA from either naked
self-amplifying RNA or self-amplifying RNA encapsulated with lipid nanoparticle (LNP) was extracted and analyzed by RNA agarose gel electrophoresis.
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monoclonal antibody anti-NTPase-II (1:2000 dilution) that has
been raised in our laboratory (Tan et al., 2010) as the primary
antibody. Finally, cells were stained with 0.5 µg/mL DAPI
for 10 min and the fluorescent images were obtained with
a fluorescence microscope (Nikon, Japan). Additionally, the
expression of NTPase-II was further analyzed by Western blot
using anti-NTPase-II monoclonal antibody. Cell lysates from
either non-transfected or RREP-eGFP-transfected cells were used
as a negative control, recombinant NTPase-II was used as a
positive control.
Lipid Nanoparticle (LNP) Encapsulation
of RNA
The preparation of LNP and encapsulation of RNA were
identical with the previous description (Geall et al., 2012; Ma
et al., 2014). Briefly, the LNP, consisting of 1,2-distearoyl-
sn-glycero-3-phosphocholine (DSPC, Sigma–Aldrich, USA),
cholesterol (Sigma–Aldrich), 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]
(ammonium salt) (PEG DMG 2000) (Avanti Polar Lipids, USA),
and 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA)
synthesized as reported previously (Heyes et al., 2005) was
produced by ethanol dilution process at 10:48:2:40 molar ratio
(Geall et al., 2012). Then, the self-amplifying RNA vaccines
dissolved in 100 mM citrate buffer were encapsulated in LNP by
spontaneous vesicle formation process as previously described
(Ma et al., 2014). The resulting RNA/LNP was dialyzed against
PBS overnight at 4◦C and finally sterile-filtered through a
0.22 µm filter. Prior to vaccination, samples were diluted to the
indicated RNA concentration with PBS.
Evaluation of Encapsulation Efficiency
and RNase Protection
Ribonucleic acid/lipid nanoparticle formulations were
characterized for encapsulation efficiency and the ability to
protect the encapsulated RNA from RNase as previously
described (Geall et al., 2012). To determine the encapsulation
efficiency, the percentages of encapsulated RNA were determined
by detecting the RNA concentrations of both outside and
inside the LNP using Quant-iTTM RiboGreen R© RNA Assay Kit
(Invitrogen, USA) according to the manufacturer’s instructions.
Briefly, RNA/LNP samples were diluted in TE buffer prior to
addition of the dye, and the RNA concentrations outside the LNP
were determined by detecting the fluorescence with a microplate
reader (BioTek, USA). Afterward, the total RNA concentrations,
including the RNA outside and inside LNPs, were obtained
after the lipid membranes were breached using Triton X-100.
To evaluate RNase protection of the encapsulated RNA, the
RNA/LNP samples were treated with RNase A (Invitrogen,
USA) for 30 min. After RNase inactivation with proteinase K
(Invitrogen, USA), RNA was extracted and denaturing agarose
gel electrophoresis was performed.
Immunization
One hundred 6- to 8-week-old female BALB/c mice were divided
into 5 groups with 20 mice per group. They were injected
intramuscularly into bilateral quadriceps with 10 µg of vaccines
diluted in PBS on day 0 and 21. Mice that received PBS were used
as non-immunized control. For the determination of specific
antibodies, serum samples from all groups were obtained 14 days
after the last immunization. For the analysis of cellular immune
responses, 5 spleen samples from each group were aseptically
collected on day 35.
Evaluation of Humoral Response
Specific anti-NTPase-II IgG antibody levels were measured by
ELISA according to our previous description (Tan et al., 2011)
with minor modifications. In brief, ELISA plates (Corning, USA)
were coated overnight at 4◦C with 5 µg/mL purified recombinant
NTPase-II protein. After washing three times with PBS plus
0.05% Tween 20 (PBST), the coated plates were blocked with
5% skim milk in PBST for at least 1 h at 37◦C. Afterward,
100 µL of twofold serial dilution of serum samples from 1:100
in PBST solution were added and incubated for 1 h at 37◦C. After
washing, specific anti-NTPase-II total IgG or IgG isotype were
detected by incubating plates with 100 µl of HRP-conjugated
rabbit anti-mouse IgG, IgG1, or IgG2a (Invitrogen, USA) for
1 h at 37◦C. The plate was washed extensively, and incubated
with 100 µl of 3,3,5,5-tetramethylbenzidine (TMB). The reaction
was stopped by adding 50 µl of 2.5 N H2SO4 after 10 min, and
the optical density at 450 nm was detected with a microplate
reader. Endpoint titers were calculated or at the dilution when
the absorbance fell below 0.2.
Evaluation of Cellular Response
Two weeks after the last booster immunization, five mice per
group were sacrificed to obtain single splenocyte suspensions as
described previously (Tan et al., 2011). After erythrocytes were
lysed, the splenocytes were resuspended and plated in triplicate
in 96-well plates (3 × 105 cells/well) in presence of 10 µg/ml
recombinant NTPase-II proteins or in plain complete medium as
negative control or 5 µg/ml ConA as positive control. Plates were
incubated for 72 or 96 h at 37◦C and 5% CO2.
For lymphocyte proliferation assay, the stimulated splenocytes
were cultured for 72 h, and the spleen lymphocyte proliferative
activity was detected with CCK-8 reagent (Dojindo Laboratories;
Kumamoto, Japan) in accordance to the manufacturer’s
instruction. The absorbance at 450 nm was read, and then,
the stimulation index (SI) was calculated as the ratio of the
average OD450 value from recombinant NTPase-II-stimulated
cultures/the average OD450 value from cells with medium
cultures.
For IFN-γ analysis, cell-free supernatants from the stimulated
splenocytes were collected and the IFN-γ activity was analyzed
at 96 h after stimulation. According to the manufacturer’s
instructions of Mouse IFN-γ ELISA Ready-SET-Go! R©
(eBioscience, USA), their IFN-γ concentrations were determined
by reference to a standard curve constructed with known
amounts of mouse IFN-γ and the sensitivity limit was 15 pg/ml.
Challenge Infection
Two weeks after the last booster immunization, five mice per
group were infected intraperitoneally with 103 tachyzoites of RH
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strain and observed for an additional 30 days. The survival time
and the percentages of mice survived were recorded daily.
In addition, 10 mice of each group were orally challenged with
20 tissue cysts of PRU strain on day 35. Mortality was observed
daily for 45 days, and the surviving mice were sacrificed for
quantification of cysts in brain as described previously (Tan et al.,
2011).
Statistical Analysis
Statistical analysis was carried out with one-way ANOVA and
multiple comparison procedures using SPSS 13.0 software for
each assay, and Kaplan–Meier test for survival analysis. Data were
represented as the mean ± SEM. Differences were considered
statistically significant when p< 0.05.
RESULTS
Detection of Expression of NTPase-II
by IFA
Plasmid pRREP-NTPase-II as templates for transcription of RNA
was constructed successfully by verification with sequencing
(data not shown). For the assessment of protein expression
in vitro, transfection of self-amplifying RNA into 293T cells was
performed at once post-transcription and capping. At 24 h post-
transfection, expression of the NTPase-II protein was verified
by IFA with specific monoclonal antibody. The fluorescence
was observed in the cells transfected with self-amplifying RNA,
whereas no fluorescent signal was observed in the negative
control (Figure 1B), demonstrating that NTPase-II protein
could be expressed in mammalian cells. The identity of the
expressed NTPase-II protein was further confirmed by Western
blot. A single protein band was detected at the size of about
70 kDa corresponding to the predicted size of NTPase-II protein
(Figure 1C).
RNA/LNP Vaccine Characterization
After RNA was encapsulated in LNP, characteristics of RREP-
NTPase-II/LNP formulations were analyzed. For the assessment
of encapsulation efficiency, the concentrations of both free RNA
and total RNA in solution post-encapsulation were measured.
The result showed that ∼80% of the RNA was encapsulated.
In addition, the integrity of encapsulated RNA was validated
by denaturing agarose gel electrophoresis after treatment with
RNase A (Figure 1D). The result showed that the encapsulated
RNA was maintained, while the naked RNA was degraded by
RNase A, demonstrating that the LNP has the ability to protect
the encapsulated RNA from degradation.
Evaluation of the Humoral Immune
Response
In order to evaluate if the immunization with self-amplifying
RNA vaccine encoding NTPase-II antigen induced specific
humoral immune response, the antibody titers in serum samples
from immunized mice were detected by indirect ELISA 2 weeks
after last vaccination. Results were presented as the mean of
log10 titers ± SEM. As a result, a significantly higher NTPase-
II-specific IgG titers were observed in groups immunized with
RREP-NTPase-II (2.466 ± 0.206, p < 0.001) in contrast to
three control groups, PBS (0.495 ± 0.040), RREP (0.60 ± 0.07),
and RREP/LNP (0.656 ± 0.069; Figure 2A). In an additional
experiment, the distribution of both IgG1 and IgG2a was also
analyzed (Figures 2B,C). The levels of both IgG subtypes were
significantly increased in mice immunized with RREP-NTPase-
II (p < 0.001). Noteworthy, RREP-NTPase-II vaccine elicited
slightly higher specific IgG2a (2.625 ± 0.174) levels when
compared to IgG1 (1.59± 0.019), consistent with a Th1 response.
Furthermore, to investigate if LNP improved the humoral
immune responses, mice were immunized with 10 µg of
encapsulated RNA (RREP-NTPase-II/LNP). The encapsulated
RNA elicited significantly higher total IgG (3.879 ± 0.173,
p < 0.001) as well as both IgG subtypes titers, IgG1
(3.095 ± 0.106) and IgG2a (3.970 ± 0.094), than naked RNA
(RREP-NTPase-II). Similarly, a Th1 response was elicited in
immunized mice. These results indicate that the presence of LNP
enhances the specific humoral immune response.
Evaluation of the Cellular Immune
Responses
Two weeks after last vaccination, splenocytes were harvested
from immunized mice and an in vitro lymphocyte proliferation
assay was performed. Both RREP-NTPase-II (2.454 ± 0.221,
p< 0.001) and RREP-NTPase-II/LNP (3.656± 0.317, p< 0.001)
elicited a significantly higher SI values to the NTPase-II
antigen stimulation. On the contrary, administration with
PBS (1.098 ± 0.100), RREP (1.240 ± 0.129), or RREP/LNP
(1.482 ± 0.143) induced little lymphocyte proliferation to
NTPase-II stimulation (Figure 3A).
To further determine if immunization with self-amplifying
RNA vaccine induced a cellular immune response, the
concentration of IFN-γ in supernatants of splenocytes
stimulated with NTPase-II antigen was measured. Upon
stimulation, RREP-NTPase-II (214.10 ± 46.01) produced
significantly higher levels of IFN-γ (p < 0.001). For RREP-
NTPase-II/LNP (451.34 ± 16.26), the positive effect was even
more pronounced and increased twofold than those from
RREP-NTPase-II (p < 0.01). In contrast, neither the PBS control
group (18.05 ± 1.98) nor the groups that immunized with
RREP (16.59 ± 2.75) or RREP/LNP (23.64 ± 2.29) developed
any detectable amount of IFN-γ (Figure 3B). These results
suggest that RNA/LNP was able to elicit the antigen-specific
IFN-γ-mediated responses.
Assessment of Protective Efficacy
Against T. gondii Infection
To evaluate if self-amplifying RNA vaccine could confer effective
protection against T. gondii acute infection, five mice per group
were challenged with 103 RH strain tachyzoites 2 weeks after
boosting (Figure 4A). All mice immunized with PBS, RREP,
or RREP/LNP died within 9 days after challenge. However,
a significantly prolonged survival time was observed in mice
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FIGURE 2 | Determination of specific humoral response in the immunized mice. Two weeks after immunization, sera were obtained and NTPase-II-specific
total IgG (A), IgG1 (B), and IgG2a (C) titers were determined by ELISA. Data are plotted as end point titers and shown for each individual mouse. Results are
expressed as the mean of log10 titers ± SEM and are representative of at least two independent experiments. ∗∗∗p < 0.001; ns, not significant.
FIGURE 3 | Cellular responses in splenocytes isolated from the immunized mice. Two weeks after immunization, splenocytes were harvested from five mice
per group. After stimulation with recombinant NTPase-II (10 µg/mL), cellular immune responses were analyzed. (A) Lymphocyte proliferative assay. Seventy-two
hours after stimulation, the lymphocyte proliferative response was detected and expressed as stimulation index (SI). (B) IFN-γ production. Supernatants of
stimulated splenocytes were assessed by ELISA for the production of IFN-γ at 96 h after stimulation. Data represent the mean ± SEM and are representative of at
least two independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001; ns, not significant.
immunized with both RREP-NTPase-II and RREP-NTPase-
II/LNP (p< 0.01). Especially in the RREP-NTPase-II/LNP group,
one mouse still survived after 30 days of challenge, which showed
the highest survival rate and was significantly higher than that of
the RREP-NTPase-II group (p< 0.01).
Furthermore, the resistance to T. gondii chronic infection was
also evaluated. The immunized mice were challenged with 20
PRU strain cysts 2 weeks after last immunization (Figure 4B).
Forty-five days after the challenge, direct cyst counting was
performed by optical microscopy in the brains of survived
mice. Similar to the results of acute challenge, the number
of brain cysts showed a significant reduction in both RREP-
NTPase-II by 46.4% (1402.00 ± 225.50, p < 0.05) and RREP-
NTPase-II/LNP by 62.1% (897.30 ± 98.22, p < 0.01) compared
with PBS (2370.17 ± 310.36), RREP (2245.86 ± 319.89),
or RREP/LNP (2231.67 ± 306.02). Therefore, immunization
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FIGURE 4 | Protection of BALB/c mice against T. gondii infection.
(A) Survival rate of vaccinated mice after RH strain tachyzoites challenge. Two
weeks later post-immunization, five mice per group were intraperitoneally
infected with 103 live RH strain tachyzoites and observed daily for mortality.
The final survival rates were calculated, ∗∗p < 0.01. (B) The cyst number in
brain after PRU strain cyst challenge. Another 10 mice per group were
challenged by gavage with 20 PRU strain cysts; 45 days after challenge, brain
cysts were counted in surviving mice. Data represent the group mean ± SEM.
The results presented are representative of two independent experiments.
∗p < 0.05 and ∗∗p < 0.01.
with self-amplifying NTPase-II RNA encapsulated with LNP
enhanced a substantial resistance to the acute and chronic
challenges of T. gondii.
DISCUSSION
This study applies a RNA/LNP vaccination strategy, explored
for inducing protective immunity against viral infection, to
induce effective immune responses against T. gondii challenge.
Significant information obtained demonstrates that a potent
immune response could be induced by self-amplifying RNA,
and this response can be further enhanced by LNP delivery
system.
Currently, there is a popular view that the nuclear membrane
of transfected cells is attributed to the major barrier for restriction
of delivering DNA vaccine into nuclear and consequently
reduction of the expression level of AOI (Dupuis et al.,
2000). Particularly, it seems to be ineffective in non-dividing
cells, such as mature myocytes. Therefore, while many DNA
vaccines are able to induce strong immune responses in
small animals, the immunity is generally weaker in larger
animals, with the amount of DNA vaccine required for efficient
immunity being 1,000-fold higher in larger species than in small
animals (Kutzler and Weiner, 2008). In addition, although this
limitation can be surmounted by immunizing more DNA and
exploiting electroporation to promote the DNA transport from
cytoplasm into nuclear (Dupuis et al., 2000), anti-vector immune
response and hazard of vector chromosomal integration must
be considered (Smerdou and Liljestrom, 1999; Kofler et al.,
2004). On the contrary, self-amplifying RNA vaccine employed
in the present study circumvents these limitations due to its
characteristics of strict cytoplasmic replication and expression,
which improves the transfection efficient in different cell types,
diminishes the need for codon modification, and excludes the
risks of splicing and degradation (Johansson et al., 2012). To date,
the vaccination of both naked or liposome-encapsulated non-
amplifying mRNA (Weide et al., 2008, 2009; Rittig et al., 2011)
and self-amplifying RNA packaged in viral replicon particles
(VRPs; Bernstein et al., 2009) has been validated in human
clinical trials for safety as well as increased cellular or humoral
immunity. Herein, we have successfully constructed the self-
amplifying RNA plasmid vaccine, pRREP-NTPase-II, and the
expression of NTPase-II was verified by IFA and Western blot.
Although we did not directly make a comparison between the
self-amplifying RNA vaccine and DNA vaccine, we reasonably
believe the self-amplifying RNA vaccine has several advantages
than DNA vaccine because the lower dose of self-amplifying
RNA vaccine (10 µg/time) and the less time of immunization
(two times) can still elicit significant immune response in
comparison with the conventional DNA vaccine, usually requires
more than 100 µg plasmid per time and at least three times
(Angus et al., 2000; Vercammen et al., 2000; Yuan et al.,
2011).
In addition, in our study, the production and amplification of
DNA templates for in vitro transcription were completed using
standard molecular cloning techniques. The self-amplifying
RNA was then transcribed in vitro using a commercial kit,
which can produce up to milligram quantities of RNA.
Compared with other mRNA vaccine, the production of the
self-amplifying RNA not only eliminates the potential risks that
produce infectious virus via recombination, but circumvents
the immunity against viral vectors because the viral replicon
is intrinsically able to induce apoptosis of the transfected
cell, resulting in transient and self-eliminating expression of
the self-amplifying RNA vaccine (Johanning et al., 1995;
Berglund et al., 1998; Fleeton et al., 2001). Importantly,
the self-amplifying RNA is able to induce both humoral
and cellular immune responses as determined in the present
study.
Currently, many kinds of adjuvants have been applied and
reported to enhance immune responses and protection against
T. gondii in a good deal of studies. However, to our knowledge,
the LNP delivery system is not so far utilized as an adjuvant
in the development of vaccines against T. gondii, even though
it has been developed to encapsulate self-amplifying mRNA for
eliciting specific immune responses against antigens from HIV
(Geall et al., 2012) or influenza virus (Hekele et al., 2013).
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In these studies, they have shown that the LNP encapsulation
dramatically improves the potency of the self-amplifying RNA
because the LNP delivery system might enhance transfection
efficiency, prevent the RNA degradation from enzymes at the
injection site, as well as boost antigen presenting cells to sequester
RNA/LNP particles, thereby promoting antigen production and
stimulating the innate immunity within these immune cells.
In the present study, we have successfully encapsulated the
self-amplifying RNA with LNP by an ethanol dilution process.
Agarose gel electrophoresis determined that LNPs provide an
effective protection of self-amplifying RNA from RNase A
degradation.
As an obligate intracellular parasitic protozoan, Th1 cell-
mediated immunity is considered to play a critical role in
protective immunity to T. gondii (Jongert et al., 2009, 2010).
IFN-γ, one of Th1-type cytokines, has been proven to be a pivotal
mediator of resistance to Toxoplasma in vivo (Suzuki et al.,
1988). Our previous studies (Tan et al., 2011) have demonstrated
that the recombinant NTPase-II protein is able to provide
protective Th1 cell-mediated immunity against Toxoplasma by
induction of lymphocyte proliferation, high IFN-γ production,
and activation of CD8+ T cells, the major T cell subset associated
with acquired immune protection against T. gondii (Suzuki
et al., 1989; Tan et al., 2011). Therefore, we paid more attention
to assess the extent of cellular immune response using spleen
lymphocytes from immunized mice. These results validated the
significantly increased lymphocyte proliferation and IFN-γ level
to Toxoplasma NTPase-II protein in mice immunized with
naked self-amplifying RNA. More importantly, the enhanced
lymphocyte proliferation response and higher IFN-γ production
were promoted by LNP encapsulation. These findings indicate
that immunization with naked self-amplifying RNA or LNP-
encapsulated RNA indeed induces the IFN-γ-related Th1-type
immunity, requiring for prevention of Toxoplasma infection,
although more experiments should be designed to further
evaluate the Th1-type immunity. Nevertheless, it is worth
noticing that the immunity induced by RNA/LNP elicits
a considerably higher protection rate than the naked self-
amplifying RNA in experimental mice against Toxoplasma
RH strain, significantly prolonging their surviving time up
to 30 days after challenge. As a result, the higher survival
rate and prolonged survival days further support that LNP
encapsulation is better in inducing strong NTPase-II-specific
IFN-γ production to sustain a protective immune response
against T. gondii.
In addition, one advantage of self-amplifying RNA is the
ability to elicit a significantly cellular memory immune response
(Johansson et al., 2012). Although the memory T-cell immune
responses were not investigated in the present study, the
better control of brain cyst burden in both self-amplifying
RNA-vaccinated mice groups during the chronic stage of
toxoplasmosis, which is dependent on long-acting memory T
cells, encourages us to speculate that self-amplifying RNA has the
capability of eliciting an increase in effector memory T cells and
the effect can be enhanced by LNP encapsulation. Also, the result
consists with our previous finding that a significant decrease
in brain cyst burden can be observed in mice vaccinated with
NTPase-II protein, suggesting that Toxoplasma NTPase-II could
be a potential vaccine candidate (Tan et al., 2011).
Although now it is not entirely clear to what extent the
function of IgG antibodies is in anti-Toxoplasma infection, a
widespread theory is that the specific IgG antibodies play a
partial role in the resistance to T. gondii during secondary
infection (Kang et al., 2000; Johnson and Sayles, 2002). In
this study, therefore, the specific IgG antibodies were also
detected in order to evaluate humoral immunity elicited by RNA
vaccine. Expectedly, an enhanced anti-NTPase-II IgG response
detected in sera from mice immunized with either naked
self-amplifying RNA or RNA/LNP was validated. Furthermore,
the serum IgG isotype profile was predominated by IgG2a,
on behalf of a stronger Th1 cell-mediated immune responses,
indicating that systemic humoral immunity elicited with RNA
vaccine may involve in the prevention of T. gondii infection.
More importantly, the IgG titers after vaccination with the
RNA/LNP were superior to those induced by vaccination of
naked RNA, which is consistent with previous findings that LNP
encapsulation promotes a stronger Th1 cell response (Geall et al.,
2012).
In summary, we have successfully encapsulated self-
amplifying T. gondii NTPase-II RNA with LNP to produce
RNA/LNP that can prevent the RNA degradation from
RNase A. The naked self-amplifying RNA is capable to
induce the protective NTPase-II-specific humoral and cellular
immune responses to protect mice from T. gondii challenge.
Additionally, RNA/LNP administered in the mouse enhances
further the protective immunity. Noteworthily, although the
partial protection was provided by this vaccine candidate,
other effective immunization strategies and multi-antigens
constructs should be included to produce better protective
immunity in the future. In any case, the capability of the
combination of self-amplifying RNA and LNP encapsulation
to successfully elicit and extend protective immune response
would be beneficial to the development of a safe and long-
acting vaccine against T. gondii for future use in animals and
humans.
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